CA2295389A1 - Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene - Google Patents

Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene Download PDF

Info

Publication number
CA2295389A1
CA2295389A1 CA002295389A CA2295389A CA2295389A1 CA 2295389 A1 CA2295389 A1 CA 2295389A1 CA 002295389 A CA002295389 A CA 002295389A CA 2295389 A CA2295389 A CA 2295389A CA 2295389 A1 CA2295389 A1 CA 2295389A1
Authority
CA
Canada
Prior art keywords
disorders
treatment
estrogens
nausea
vomiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002295389A
Other languages
English (en)
Other versions
CA2295389C (fr
Inventor
Joy Ann Steele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002295389A priority Critical patent/CA2295389C/fr
Publication of CA2295389A1 publication Critical patent/CA2295389A1/fr
Application granted granted Critical
Publication of CA2295389C publication Critical patent/CA2295389C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA002295389A 2000-01-04 2000-01-04 Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene Expired - Lifetime CA2295389C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002295389A CA2295389C (fr) 2000-01-04 2000-01-04 Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002295389A CA2295389C (fr) 2000-01-04 2000-01-04 Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene

Publications (2)

Publication Number Publication Date
CA2295389A1 true CA2295389A1 (fr) 2001-07-04
CA2295389C CA2295389C (fr) 2006-07-11

Family

ID=4165054

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295389A Expired - Lifetime CA2295389C (fr) 2000-01-04 2000-01-04 Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene

Country Status (1)

Country Link
CA (1) CA2295389C (fr)

Also Published As

Publication number Publication date
CA2295389C (fr) 2006-07-11

Similar Documents

Publication Publication Date Title
NZ514574A (en) Novel method of treatment
GB9104890D0 (en) Compositions
IL176107A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
AU7315301A (en) Compounds and compositions for delivering active agents
AU2274201A (en) Compounds and compositions for delivering active agents
PL366430A1 (en) Sustained release formulations of oxymorphone
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
MXPA04003807A (es) Formulaciones farmaceuticas de 5, 7, 14-trianzatetraciclo [10.3.1.02, 11, 04, 9]-hexadeca -2 (11), 3, 5, 7, 9-pentaeno.
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
HK1084015A1 (en) Stable pharmaceutical compositions of 2-aza-bicyclo3.3.0 -octane-3- carboxylic acid derivatives 2-
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
EP1232757A4 (fr) Medicaments pour des affections liees a la perte de masse osseuse
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2004000840A3 (fr) Nouveaux derives de la quinuclidine et compositions medicinales les contenant
NO954878L (no) Pyrrolderivater
SE9903997D0 (sv) New compounds
WO2002015959A3 (fr) Composes et compositions permettant de distribuer des agents actifs
TW200503689A (en) Pharmaceutical compositions of atorvastatin
WO2000054780A3 (fr) Formulation corticosteroidienne
AP2001002084A0 (en) Orally administered controlled delivery system for once daily adminstration of ciprofloxacin
CA2295389A1 (fr) Methode de traitement de la nausee, du vomissement et d'autres troubles au moyen d'oestrogene
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
ES2179729A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
JO2199B1 (en) Replaced pyrrols
WO2001000187A3 (fr) Agents therapeutiques

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20200106